Kurozumi S, Alsaleem M, Monteiro CJ, Bhardwaj K, et al. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Res 2020;22:85.
PMID: 32782013